Compare · DXCM vs SSKN
DXCM vs SSKN
Side-by-side comparison of DexCom Inc. (DXCM) and Strata Skin Sciences Inc. (SSKN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and SSKN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.58B, about 604.1x SSKN ($49.0M).
- Over the past year, DXCM is down 8.8% and SSKN is down 91.1% - DXCM leads by 82.3 points.
- DXCM has hit the wire 4 times in the past 4 weeks while SSKN has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 0 for SSKN).
- Company
- DexCom Inc.
- Strata Skin Sciences Inc.
- Price
- $76.65-1.74%
- $0.19-38.08%
- Market cap
- $29.58B
- $49.0M
- 1M return
- +4.76%
- +0.00%
- 1Y return
- -8.79%
- -91.06%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2005
- News (4w)
- 4
- 0
- Recent ratings
- 25
- 0
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Strata Skin Sciences Inc.
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. Its products include XTRAC excimer laser and VTRAC lamp systems that are used for the treatment of psoriasis, vitiligo, atopic dermatitis, eczema, and other skin disorders. The company distributes its products internationally through distributors, and domestically directly to physicians. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon sold $126,514 worth of shares (1,700 units at $74.42) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 104,653 units (SEC Form 4)
- Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
- Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
- Executive Chair Sayer Kevin R sold $1,926,432 worth of shares (26,756 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 355,726 units (SEC Form 4)
- Dexcom Further Advances Vision of Glucose Biosensing for All
- Deutsche Bank initiated coverage on Dexcom with a new price target
- EVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)
- Director Foletta Mark G sold $296,540 worth of shares (4,000 units at $74.13) as part of a pre-agreed trading plan (SEC Form 4)
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
Latest SSKN
- New Peer-Reviewed Publication Confirms Unprecedented Response Rates for STRATA's Excimer Laser Combined with JAK Inhibitors in Pediatric Vitiligo
- SEC Form 10-K filed by Strata Skin Sciences Inc.
- SEC Form EFFECT filed by Strata Skin Sciences Inc.
- SEC Form EFFECT filed by Strata Skin Sciences Inc.
- SEC Form EFFECT filed by Strata Skin Sciences Inc.
- SEC Form 15-12G filed by Strata Skin Sciences Inc.
- SEC Form POS AM filed by Strata Skin Sciences Inc.
- SEC Form POS AM filed by Strata Skin Sciences Inc.
- SEC Form S-8 POS filed by Strata Skin Sciences Inc.
- SEC Form POS AM filed by Strata Skin Sciences Inc.